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ositively Magnetic North*
imothy F. Christian, MD, FACC
urlington, Vermont
But I am as constant as the northern star, of whose true-fixed
and resting quality there is no fellow in the firmament.
—William Shakespeare, Julius Caesar, Act III, scene i
lthough Oscar Wilde maintained that “consistency is the
ast refuge of the unimaginative,” readers should not skip
ver the imaging reproducibility study by Thiele et al. (1) in
his issue of the Journal. This short and eloquent study
rovides a view into the power behind new digital imaging
echnologies. Magnetic resonance viability imaging after a
olus of gadolinium-based contrast and computed tomog-
aphy coronary angiography comprise the two most impor-
ant recent advances in cardiac imaging. Magnetic reso-
ance infarct imaging provides a close-up view of cardiac
athology after myocardial infarction with vivid reflections
f necrosis staining in animal models (2,3). This has the
otential to revolutionize the field of myocardial viability.
lthough magnetic resonance imaging (MRI) provides a
esolution of approximately 1 to 2 mm in the two-
imensional plane for infarct sizing, there have been issues
aised regarding its reliability (4,5). Precision is important
ecause reproducibility is the keystone for the evaluation of
schemic heart disease.
See page 1641
Coronary artery disease tends to generate serial diagnostic
esting. We order serial echocardiograms to assess changes
n left ventricular (LV) function and nuclear single-photon
mission computed tomography (SPECT) studies to follow
he progression of ischemia over time. Central to this
ehavior is an assumption that a change in the measures
rom these tests represents a real change in individual
atient physiology. The threshold for a real change is very
uch a function of how reproducible the test is over time in
he absence of change. One cannot simply acquire an image
nce and read it blinded twice or even acquire it twice on the
ame day to get a handle on temporal variability. To know
hat is real, we need to know what noise is. Although this
ight seem self-evident, the cardiology literature is largely
evoid of carefully performed temporal reproducibility stud-
es, with exceptions (6,7). Consequently, for many tests, we
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ecipient of an American Heart Association Grant-in-aid award on MRI-based
igh-field perfusion imaging.o not have a handle on how consistent they are over time
n the absence of physiological change.
In the present study by Thiele et al. (1), with simple
ubjective manual tracing of digital images in patients with
history of acute or chronic infarction, the reproducibility
f an MRI viability image acquired on two separate days was
uite close (95% confidence limits were 2.4% infarct size
s a percent of the LV) and virtually identical to values
btained previously with same-day dual acquisitions (8).
his is a new level in precision for the temporal imaging of
schemic heart disease. Consequently, the dichotomization
f tissues on the basis of viability by MRI seems to contain
ittle noise within the measure. But it does not provide more
han a dichotomization. There is no information regarding
he metabolic state of the remaining viable tissue, although
uch can be inferred in conjunction with regional wall
otion and perfusion (usually obtained in the same exam-
nation).
Why are the reproducibility results for MRI infarct sizing
o impressive? Unlike SPECT perfusion imaging or echo-
ardiographic wall motion, MRI deals with a positive
mage. Infarcts can be seen and at high spatial resolution.
his is because of the accumulation of gadolinium within
he extracellular space of the necrotic tissue. We are not
ealing with the absence of something where the boundaries
ave to be estimated. Viability imaging is about separating
issues. Consequently, a threshold must be selected on the
asis of some aspect of the image that reflects viability.
sually this is a function of the signal intensity that a tracer
enerates (either positively or negatively) on the basis of its
istribution within the myocardium: the sharper the bor-
ers, the cleaner the cut.
Tc-99m sestamibi imaging has been used effectively in
he past for infarct sizing. Because of the lower resolution of
PECT image acquisition and the associated photon scat-
er, even in a severely transmural defect like the one shown
n Figure 1, the borders between viable and necrotic
yocardium are sloped. Because such thresholds are usually
aken as a percent of the maximal myocardial activity, they
re subject to some variability by threshold choice and
ormalization zone. The depth at which a threshold is
laced will alter the infarct size measure (9). Magnetic
esonance viability imaging is a scatter-free high resolution
echnique and, therefore, is relatively independent of the
hreshold value. With such sharp interfaces, reproducibility
s not impacted by physical parameters. Automated quan-
itation programs might further improve consistency; how-
ver, most inexperienced observers could consistently trace a
agnetic resonance (MR)-derived infarct volume from
igure 1.
The MR viability imaging has now been validated exten-
ively with histopathology staining in animal models (2,3),
redicted improvement in wall motion with revasculariza-
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April 18, 2006:1646–8 Editorial Commention and medical therapy (10,11), correlated with other
urrogate measures of infarct size (12), detected micro-
ecrosis post-intervention (13), resolved subendocardial
rom transmural infarction (14), and been reproducible to a
igh level in both patients with chronic and recent infarc-
ion (1,8). Although the authors focused on the immediate
enefit of reduced sample sizes required to a show an impact
n infarct size for clinical trials, the more important benefit
s in clinical care. By accurately quantifying infarct volume
nd transmurality, MRI provides a tool in-hand to gauge
he benefit of reperfusion therapy in individual patients and
o quantify potential jeopardized myocardium for the future.
hat is a lesson that should not be lost. The lateral edges of
n infarct are crisp and established early in the course of an
cute occlusion (15), with necrosis proceeding from inside-
ut. By measuring the subendocardial infarct volume, we are
imultaneously measuring what did not infarct subepicardi-
igure 1. Two short-axis midventricular images from separate patients wh
patient with inferolateral infarction (arrows) demonstrated by single-pho
nd the bottom row is a patient with anteroseptal infarction demonstrated
n inversion recovery gradient sequence after gadolinium administration. Th
mage. For these types of displays, the short-axis circular image is divided
ngle (x-axis). The signal intensity (y-axis) along the thin circular region o
hape of the SPECT curve as compared with the delta function–like appe
epresent 70% (light gray), 60% (dark gray), and 50% (black) threshold v
ore potential variability for SPECT determinations.lly. Together, these two volumes might provide a retro- bpective quantitation of the myocardial risk area. The
otential value of this measure should not be underesti-
ated (16).
There are two phases to the evaluation of clinical tests: the
fficacy phase, where the feasibility and accuracy of the test is
valuated; and the effectiveness phase, where the technology is
pplied broadly to a clinical population. The efficacy phase
f MR viability imaging is over. It is a powerful, nonradio-
ctive, non-nephrotoxic tool that consistently provides mea-
ures of infarct volume with little declination from “true
orth.”
The effectiveness phase is in progress. There are issues to
ackle for MR viability imaging. The cost is high and
ariable and reflects billing codes developed in the earlier
ays of long MR exams. A complete cardiac exam for
schemic heart disease may be acquired within 45 min. A
5-min “viability only” exam, where contrast is injected
e suffered transmural myocardial infarction. The top row shows data from
ission computed tomography (SPECT) imaging with Tc-99m sestamibi,
agnetic resonance imaging (MRI) delayed hyperenhanced imaging using
phs on the right side represent a circumferential intensity profile from each
60° with the tracer or signal intensity displayed linearly with the location
rest is plotted as a function of angle location. Note the inverted wave-like
e of the MR curve when the infarct is encountered. The shaded arrows
of signal intensity for infarct size measurements (arrow width). There iso hav
ton em
by m
e gra
into 3
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arancefore the patient enters the magnet, might provide im-
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Editorial Comment April 18, 2006:1646–8roved effectiveness at lower cost. Arrhythmias and im-
lanted cardiac devices remain issues for MRI.
It is hard to abandon methods that have worked well in
he past. But the essence of advancement is willingness to
ccept change. We should not be afraid to jump into this
echnology. The MR viability imaging is a simple sequence,
asy to perform, packed with information that will be shown
o be prognostically powerful and begs for a chance to prove
ts clinical effectiveness.
Set the imaging compass to the constant northern star
nd you won’t get lost. There is no fellow in the firmament.
eprint requests and correspondence: Dr. Timothy F. Christian,
aird 191, MCHV, University of Vermont, 111 Colchester Avenue,
urlington, Vermont 05401. E-mail: timothy.christian@uvm.edu.
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